Remedios Quirce
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Remedios Quirce has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Jose Antonio Riancho
Servicio de Medicina Interna, Hospital U.M. Valdecilla, Santander, Spain; Universidad de Cantabria, Santander, Spain; Instituto de Investigación M. Valdecilla (IDIVAL), Santander, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain, Spain
2 shared publications - Alvaro del Real
Servicio de Genética, Hospital U.M. Valdecilla, Santander, Spain
1 shared publication - Ana Carina Ferreira
Department of Nephrology, Hospital Curry Cabral – Unidade Local de Saúde de São José , Lisbon
1 shared publication - Ana Elísabet López-Sundh
Department of Dermatology Hospital Universitario Marqués de Valdecilla Santander Spain
1 shared publication - Ana Isabel Vega
Servicio de Genética, Hospital U.M. Valdecilla, Santander, Spain
1 shared publication - Aníbal Ferreira
Nephrology Department, Hospital Curry Cabral, Unidade Local de Saúde São José, Lisbon, Portugal
1 shared publication
Latest Publications
- Open Access
- 30 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (17) , 6150
Novel Association of the Presenilin-1 (Leu282Arg) Mutation with Isolated Spastic Paraparesis: Case Presentation and Review of Current Evidence
Background: Although Presenilin-1 (PSEN1) mutations are classically associated with early-onset Alzheimer’s disease (AD), spastic paraparesis (SP) may occasionally represent as an initial or even isolated clinical manifestation. Methods: We report the novel association of a PSEN1 mutation (Leu282Arg) with isolated SP at onset in a patient with a family history of early-onset AD. Additionally, we reviewed previously published cases describing similar presentations related to PSEN1 mutations. Results: The age of reported patients ranged from 24 to 60 years. The most common clinical course included the presence of cotton wool plaques and a progressive development of cognitive decline following the onset of SP. A positive family history of either motor or cognitive symptoms was consistently observed. Conclusions: Our findings emphasize the clinical importance of considering PSEN1 mutations in the differential diagnosis of patients presenting with spastic paraparesis, particularly in the presence of cognitive symptoms, cerebral amyloid angiopathy, or a family history of AD.
- 30 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (17) , 6150
Open AccessNovel Association of the Presenilin-1 (Leu282Arg) Mutation with Isolated Spastic Paraparesis: Case Presentation and Review of Current Evidence
Background: Although Presenilin-1 (PSEN1) mutations are classically associated with early-onset Alzheimer’s disease (AD), spastic paraparesis (SP) may occasionally represent as an initial or even isolated clinical manifestation. Methods: We report the novel association of a PSEN1 mutation (Leu282Arg) with isolated SP at onset in a patient with a family history of early-onset AD. Additionally, we reviewed previously published cases describing similar presentations related to PSEN1 mutations. Results: The age of reported patients ranged from 24 to 60 years. The most common clinical course included the presence of cotton wool plaques and a progressive development of cognitive decline following the onset of SP. A positive family history of either motor or cognitive symptoms was consistently observed. Conclusions: Our findings emphasize the clinical importance of considering PSEN1 mutations in the differential diagnosis of patients presenting with spastic paraparesis, particularly in the presence of cognitive symptoms, cerebral amyloid angiopathy, or a family history of AD.
- Open Access
- 14 March 2025
- Published by Springer Nature in Calcified Tissue International
- Vol. 116 (1) , 1-7
Osteomesopyknosis: A Bone-Sclerosing Disorder that May be Confused with Bone Metastases
Sclerosing bone disorders encompass a range of genetic and acquired diseases. The potential for bone metastases is often a significant concern, especially when multiple discrete lesions are present. Several non-malignant disorders can also produce similar patterns of bone abnormalities. Among these is osteomesopyknosis, a rare condition characterized by multiple sclerotic lesions in the axial skeleton. Only a few cases of this presumably genetic disease have been documented. In this report, we present a new case and review previously published cases to enhance understanding and facilitate recognition of this disorder within the broader category of sclerosing bone diseases.
- 14 March 2025
- Published by Springer Nature in Calcified Tissue International
- Vol. 116 (1) , 1-7
Open AccessOsteomesopyknosis: A Bone-Sclerosing Disorder that May be Confused with Bone Metastases
Sclerosing bone disorders encompass a range of genetic and acquired diseases. The potential for bone metastases is often a significant concern, especially when multiple discrete lesions are present. Several non-malignant disorders can also produce similar patterns of bone abnormalities. Among these is osteomesopyknosis, a rare condition characterized by multiple sclerotic lesions in the axial skeleton. Only a few cases of this presumably genetic disease have been documented. In this report, we present a new case and review previously published cases to enhance understanding and facilitate recognition of this disorder within the broader category of sclerosing bone diseases.
- Open Access
- 23 October 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (20) , 15467
Erdheim–Chester Disease Due to a Novel Internal Duplication of NRAS: Response to Targeted Therapy with Cobimetinib
Histiocytoses encompass a group of exceptionally rare disorders characterized by the abnormal infiltration of tissues by histocytes. Among these, Erdheim–Chester disease (ECD) stands out as a multisystem histiocytosis that typically affects bones and various other tissues. Historically, the treatment of ECD has been challenging. However, recent breakthroughs in our understanding, particularly the discovery of somatic mutations in the RAS-MAPK pathway, have opened new opportunities for targeted therapy in a significant subset of patients with ECD and other histiocytoses. In this report, we present the case of a patient with ECD harboring a previously unidentified microduplication in the NRAS gene in a small fraction of skin cells. This discovery played a pivotal role in tailoring an effective therapeutic approach involving kinase inhibitors downstream of NRAS. This case underscores the crucial role of deep sequencing of tissue samples in ECD, enabling the delivery of personalized targeted therapy to patients.
- 23 October 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (20) , 15467
Open AccessErdheim–Chester Disease Due to a Novel Internal Duplication of NRAS: Response to Targeted Therapy with Cobimetinib
Histiocytoses encompass a group of exceptionally rare disorders characterized by the abnormal infiltration of tissues by histocytes. Among these, Erdheim–Chester disease (ECD) stands out as a multisystem histiocytosis that typically affects bones and various other tissues. Historically, the treatment of ECD has been challenging. However, recent breakthroughs in our understanding, particularly the discovery of somatic mutations in the RAS-MAPK pathway, have opened new opportunities for targeted therapy in a significant subset of patients with ECD and other histiocytoses. In this report, we present the case of a patient with ECD harboring a previously unidentified microduplication in the NRAS gene in a small fraction of skin cells. This discovery played a pivotal role in tailoring an effective therapeutic approach involving kinase inhibitors downstream of NRAS. This case underscores the crucial role of deep sequencing of tissue samples in ECD, enabling the delivery of personalized targeted therapy to patients.